Usually, drug companies get years of exclusive marketing rights before a drug runs into generic competition, but that's not the case for Johnson & Johnson
On Friday, both Perrigo
J&J acquired the rights to the over-the-counter version when it purchased Pfizer's
With generic competition, J&J won't be able to fetch nearly as high a price for the drug, but the over-the-counter status should help it reach a larger audience than Pfizer's prescription version did. In its new shelf spot, it will have to compete with other over-the-counter antihistamines including Schering-Plough's
For a company the size of J&J, a little added generic competition isn't going to have too large an effect. But it is a sign of the growing patent problem for Big Pharma in general and J&J specifically -- both its antipsychotic Risperdal and its Alzheimer's medication Reminyl lose patent protection next year.
More Foolishness available OTC:
Johnson & Johnson is a pick of the Income Investor newsletter service. If you'd like to see more ideas for stocks that pay dividends, grab a 30-day free trial of the service and check out all of our past recommendations.
More from The Motley Fool
3 Dividend Stocks That Pay Out Over $8 Billion a Year
Can these huge companies keep the big dividend bucks flowing?
Johnson & Johnson Aims to Start 2018 Healthy
Investors have high hopes for the healthcare conglomerate.
Is Johnson & Johnson a Buy?
Is now a good time to invest in the healthcare titan's stock?